3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
16
Genitourinary
8
Gastrointestinal
8
Breast
5
Sarcoma
3
Tumor-Agnostic
2
Thoracic
2
Other hematologic neoplasm
2
NET
2
Myeloid
2
Lymphoid
2
Head & Neck
2
Endocrine
2
CNS
2
Plasma cell
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Small Cell Lung Carcinoma
1
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
88
pembrolizumab
77
Pemetrexed
65
Cisplatin
56
Paclitaxel
33
Docetaxel
31
durvalumab
28
atezolizumab
28
Nivolumab
28
Specimen Handling
25
Magnetic Resonance Spectroscopy
20
Gemcitabine
19
osimertinib
18
130-nm albumin-bound paclitaxel
18
Etoposide
17
Radiotherapy
14
Cetuximab
14
Platinum
12
Taxes
11
Immunoglobulin G
10
1,2-diaminocyclohexaneplatinum II citrate
10
Radiation
9
Ipilimumab
9
Disulfides
9
Bevacizumab
9
amivantamab
8
Topotecan
8
fludarabine
7
Ramucirumab
7
Radiosurgery
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
olaparib
×
Thoracic
×
30 days
×
Clear all
NCT04624204
2026-05-26
MK 7339-013
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
672 enrolled
NCT04380636
2026-05-15
MK-7339-012
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
870 enrolled